SweetSpot re-analyzes completed clinical trial evidence to identify, rank and validate new indications for your assets — giving your development and investment committees a defensible answer in days, not years.
Preclinical models poorly predict patient outcomes, and efficacy often fails despite strong safety and pharmacology signals. The highest-leverage decision your team makes is which indication to pursue — and it's usually made with incomplete evidence.
% fail Phase I → II
% fail Phase II → III
% fail Phase III → Approval
% overall attrition rate
We combine clinical trial biostatistics, drug pharmacology and AI-driven analytics into a single, decision-ready workflow for indication strategy.
Surface clinically meaningful new indications from evidence your organization already owns or can access.
Select indications and optimize endpoints before you commit capital to a new trial.
Compare your asset against competitors on the same evidence-based scale.
Build the evidence package that supports approval probability and commercial value.
A rigorous, four-step pipeline — no new trial required, no proprietary datasets, no manufacturer authorization needed.
RCT data, drug mode of action and disease landscape are aggregated and harmonized.
Bayesian probability-of-success modeling predicts effect in new indications.
Effect sizes are validated against comparable assets and standards of care.
A ranked, investor-ready indication strategy — delivered in 24 hours.
A running record of what the platform finds when it re-mines completed trials — including what it rejects.
PhD statistician with +30 years of drug development experience. Founded SweetSpot to combine medical expertize, drug pharmacology and quantitative science into a repeatable indication-finding discipline.
SweetSpot is a next-generation drug development company.
Registered Office
182 Ayias Fylaxeos, Limassol, Cyprus
"SweetSpot was useful to select better endpoints for our Phase III respiratory program. It identified a strong new indication signal in a comparative asset."
"SweetSpot uncovered a potential line extension for an approved product, showing strong pharmacological evidence of improved peripheral perfusion leading to better organ preservation."
"We request SweetSpot reports on shelved assets that our BD teams have identified. They are part of our investment strategy sourcing."
"By identifying an alternative route of administration, SweetSpot provided a clear risk mitigation strategy that bypassed systemic toxicity issues and revived a high-potential asset."
Schedule a demonstration and we'll walk your leadership team through a live indication assessment for one of your assets.